Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Optometry
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2026 / July / Calcium Channel Blockers and POAG Risk
Glaucoma Research & Innovations News

Calcium Channel Blockers and POAG Risk

Common blood pressure drugs could increase risk of glaucoma progression, warns new study

7/1/2026 2 min read

Share

  • Full Article
  • Summary
  • Takeaways
  • Report
  • Poll
  • Top Institutions

Calcium Channel Blockers and POAG Risk

Overview

A large retrospective cohort study indicates that calcium channel blockers (CCBs) may be associated with higher rates of progression to severe primary open-angle glaucoma (POAG). Both dihydropyridine and nondihydropyridine CCBs were associated with significantly higher rates of progression compared to matched controls not taking these medications.

Background

Calcium channel blockers are commonly prescribed for cardiovascular conditions, yet their ocular effects remain controversial. Understanding the relationship between CCBs and glaucoma progression is crucial. The findings from this study highlight the need for further investigation into the mechanisms linking CCB use to glaucoma.

Data Highlights

Medication TypeProgression Rate (%)Control Rate (%)
Dihydropyridine CCBs3.52.1
Nondihydropyridine CCBs6.91.9

Key Findings

  • Dihydropyridine CCBs associated with a 67% higher relative risk of progression to severe POAG compared to controls.
  • Nondihydropyridine CCBs associated with more than a threefold increased risk of progression compared to controls.
  • Progression rates were significantly higher in both CCB user groups compared to matched controls.
  • The study did not establish causation and noted limitations such as reliance on ICD-10 coding and lack of detailed intraocular pressure and visual field data.
  • Potential mechanisms for increased risk include blood flow diversion and neurodegenerative processes.

Clinical Implications

Healthcare providers should be aware of the potential risks associated with CCB use in patients with POAG. Increased monitoring may be warranted for patients taking these medications to identify early signs of disease progression.

Conclusion

The study indicates an association between CCB use and increased risk of severe POAG progression.

Related Resources & Content

  1. ASCO Post, 2013 -- Long-Term Current Use of Calcium Channel Blockers Is Associated With Higher Risk of Breast Cancer
  2. Clinical Rheumatology -- Impact of Calcium Channel Blockers on Digital Ulcers in Patients with Systemic Sclerosis: Insights from a Prospective Cohort Analysis
  3. conexiant -- Calcium Score Model Tested in Chest Pain
  4. Primary Open-Angle Glaucoma Preferred Practice Pattern®, Icahn School of Medicine at Mount Sinai
  5. Reduction of Intraocular Pressure and Glaucoma Progression
  6. glaucoma physician — POAG Diagnosis May Impact Mental Health
  7. Primary Open-Angle Glaucoma Preferred Practice Pattern® - Icahn School of Medicine at Mount Sinai
  8. Reduction of Intraocular Pressure and Glaucoma Progression
  9. Checking your browser - reCAPTCHA

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: